Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.
about
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung CancerRole of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsThe Role of Hypofractionated Radiation Therapy with Photons, Protons, and Heavy Ions for Treating Extracranial LesionsRole of FNAC, fluid specimens, and cell blocks for cytological diagnosis of lung cancer in the present eraTreatment of advanced squamous cell carcinoma of the lung: a reviewA current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancerCurrent Status and Development of Traditional Chemotherapy in Non-small Cell Lung Cancer under the Background of Targeted TherapyNovel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancerMaintaining clarity: Review of maintenance therapy in non-small cell lung cancerCan microRNAs improve the management of lung cancer patients? A clinician's perspectiveThe pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysisSecond-Line Therapy for Advanced NSCLCMaintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea50 Years of progress in the systemic therapy of non-small cell lung cancerMaintenance therapies for non-small cell lung cancerGefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic reviewChina Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)Promising targets and current clinical trials in metastatic squamous cell lung cancerInternational association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaComplex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancerImproved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment?Reinforcement learning strategies for clinical trials in nonsmall cell lung cancerCost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population.A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancerPhase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancerPhase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer.NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance statusPRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-sPhase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer.Efficacies and adverse reactions of modified vitamin supplement programs before pemetrexed chemotherapy as a second-line treatment against epidermal growth factor receptor (EGFR) mutant wild-type lung adenocarcinoma.Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer.
P2860
Q22241671-08854709-D99C-401B-9352-43D729D164B8Q26767275-C8FC79D3-B1D6-40C8-BE71-A0C719F53978Q26770254-8C113057-96D3-4B71-BC49-E39B5B99D083Q26774726-89040344-2805-43D9-9A0F-4D46BE23E90CQ26775392-7E196AB4-4F0A-44FB-9FE8-BFC3F17BEC81Q26781856-DB66BEF4-8CAB-43A5-A5AB-A7FFD882B06BQ26783432-CF7116DB-0EEC-474E-A6AA-E3C270BED7DBQ26827571-F5843544-BED7-417E-8646-BB72B3BAD236Q26996389-027131A5-F036-427E-AD39-807F22E0CFBCQ26999304-5354C1A0-4C3A-4C5C-9C7A-853BCCB634BFQ26999925-A00E6461-0611-4B5D-8F24-2232DFFABA89Q27002398-F34FC91F-C236-4960-8379-41E8374E57A8Q27011282-23A40641-DF01-46F5-A228-5939E051094EQ27014978-494DC07A-EDC1-4165-97B3-44E62A85355DQ27021178-EFDB7015-EFAF-48D1-BEDA-6FC3C4072EDDQ27023100-1A4643CB-B596-4E61-932F-E6028F74F9D7Q28073920-0463529D-C5D2-416F-AEED-D05465FAE36AQ28081243-6417DE99-ABF4-436E-A1E0-67EE26098A08Q28083663-2C5E4EB4-CBFA-4F84-B7BB-886DB2861C9AQ28303718-9EBF1AD2-658D-4AB2-80D8-F3212251AB3DQ30300843-3E1DFC76-22BF-4A58-A2D9-D78DD9EAF476Q30316339-1AEF52E0-9031-45D6-82DD-AEC0F5A6FA05Q30502590-5424E6C5-5F01-43FB-BC99-6D926FF9ACC9Q30977332-96032EA4-0AA6-4D08-A93E-F13620D789A9Q33392779-04E65767-A6D0-4CBF-BC53-F3D6856C2673Q33397590-88911268-4132-4C45-BCA4-386F59F875AEQ33400988-B2FE2146-B1D5-4165-A869-501CBD90DA3CQ33404332-E91F3492-A53F-43EA-AD30-5E18A4EF9448Q33404543-754C80E5-14F2-433B-B131-23A12E382AD9Q33410020-63ED915B-DD38-4859-954E-B65B7392FE5DQ33414360-0653318F-A7A5-4E5F-A77B-344F67B7D59AQ33417324-306A982A-CE1D-46AE-9F0C-CDD84623CFE0Q33418542-F010794C-B854-4605-AF5F-427265CBCEC2Q33418595-72D7E3AD-EB1E-4E85-B09D-E9FAFC351774Q33419105-C0D30009-5FC2-48BE-B6CE-36F2E2D78559Q33424102-31E33EF6-7735-4A85-831A-7E60DA3CD592Q33427414-9B4439DB-D196-4FEB-AE66-45F13934A831Q33429869-6D9B2F75-6394-469D-AB3A-C632FEF729DFQ33432327-AEE90921-08EE-4DE6-B033-A5BD7ACE5D93Q33432898-15C50F40-A7B1-46DD-AB83-34212BC6C03A
P2860
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Maintenance pemetrexed plus be ...... , double-blind, phase 3 study.
@en
Maintenance pemetrexed plus be ...... , double-blind, phase 3 study.
@nl
type
label
Maintenance pemetrexed plus be ...... , double-blind, phase 3 study.
@en
Maintenance pemetrexed plus be ...... , double-blind, phase 3 study.
@nl
prefLabel
Maintenance pemetrexed plus be ...... , double-blind, phase 3 study.
@en
Maintenance pemetrexed plus be ...... , double-blind, phase 3 study.
@nl
P2093
P50
P1433
P1476
Maintenance pemetrexed plus be ...... , double-blind, phase 3 study.
@en
P2093
Branka Cucevic
Christoph Zielinski
Eckart Laack
Isabel Bover
Jayaprakash Madhavan
Joo Hang Kim
Jose Rodrigues Pereira
Katherine P Sugarman
Kurt Krejcy
Patrick Peterson
P304
P356
10.1016/S0140-6736(09)61497-5
P407
P577
2009-09-18T00:00:00Z